Fenofibrate inhibits angiogenesis in vitro and in vivo

Cellular and Molecular Life Sciences

Volumn 60, Issue 4, 2003, Pages 810-819

  Varet, J ^a   Vincent, L ^a,b   Mirshahi, P ^a,b   Pille, J V ^a   Legrand, E ^a   Opolon, P ^c   Mishal, Z ^d   Soria, J ^b   Li, H ^a   Soria, C ^a,e  

^a UNIVERSITÉ DE ROUEN   (France)

^b HÔTEL DIEU   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CNRS   (France)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

Akt; Angiogenesis; Atherosclerosis; Cyclooxygenase 2; Fenofibrate; Peroxisome proliferator activated receptor

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYCLOOXYGENASE 2; FENOFIBRATE; LY 29402; ONCOSTATIN M; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIRINIXIC ACID; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ANGIOGENESIS; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; CAPILLARY PROLIFERATION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; DISEASE MODEL; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; ISCHEMIA; LIPID BLOOD LEVEL; WOUND HEALING;

ACTINS; ANTILIPEMIC AGENTS; APOPTOSIS; CAPILLARIES; CELL CYCLE; CELL LINE; CYCLOOXYGENASE 2; DERMIS; ENDOTHELIUM; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROCETOFEN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 0038702371     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-003-2322-6     Document Type: Article

References (50)

1. Folkman J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1: 27-31
2. Groszek E. and Grundy S. M. (1980) The possible role of the arterial microcirculation in the pathogenesis of atherosclerosis. J. Chronic Dis. 33: 679-684
3. Jeziorska M. and Woolley D. E. (1999) Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries. J. Pathol. 188: 189-196
4. McCarthy M. J., Loftus I. M., Thompson M. M., Jones L., London N. J., Bell P. R. et al. (1999) Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J. Vasc. Surg. 30: 261-268
5. Lee R. T. and Libby P. (1997) The instable atheroma. Arterioscler Thromb. Vasc. Biol. 17: 1859-1867
6. Vincent L., Soria C., Mirshahi F., Opolon P., Mishal Z., Vannier J. P. et al. (2002) Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arteriosclen Thromb. Vasc. Biol. 22: 623-629
7. Vincent L., Chen W., Hong L., Mirshahi F., Mishal Z., Mirshahi-Khorassani T. et al. (2001) Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS. Lett. 495: 159-166
8. Weis M., Heeschen C., Glassford A. J. and Cooke J. P. (2002) Statins have biphasic effects on angiogenesis. Circulation 105: 739-745
9. Fruchart J. C., Staels B. and Duriez P. (2001) PPARS, metabolic disease and atherosclerosis. Pharmacol. Res. 44: 345-342
10. Watts G. F. and Dimmitt S. B. (1999) Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr. Opin. Lipidol. 10: 561-574
11. Willson T. M., Brown P. J., Sternbach D. D. and Henke B. R. (2000) The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43: 527-550
12. Pineda Torra I., Gervois P. and Staels B. (1999) Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr. Opin. Lipidol. 10: 151-159
13. Fruchart J. C., Duriez P. and Staels B. (1999) Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 10: 245-257
14. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J. M, Gonzalez F. J. et al. (1999) Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274: 32048-32054
15. Rival Y., Beneteau N., Taillandier T., Pezet M., Dupont-Passelaigue E., Patoiseau J. F. et al. (2002) PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol. 435: 143-151
16. Blann A. D., Belgore F. M., Constans J., Conri C. and Lip G. Y. (2001) Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am. J. Cardiol. 87: 1160-1163
17. Inoue I., Shino K., Noji S., Awata T. and Katayama S. (1998) Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun. 246: 370-374
18. Plutzky J. (2001) Peroxisome proliferator-activated receptors in endothelial cell biology. Curr. Opin. Lipidol. 12: 511-518
19. Ades E. W., Candal F. J., Swerlick R. A., George V. G., Summers S, Bosse D. C. et al. (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 99: 683-690
20. Vasse M., Pourtau J., Trochon V., Muraine M., Vannier J. P., Lu H. et al. (1999) Oncostatin M induces angiogenesis in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 19: 1835-1842
21. Griscelli F., Li H., Bennaceur-Griscelli A., Soria J., Opolon P., Soria C. et al. (1998) Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad. Sci. 95: 6367-6372
22. Bouis D., Hospers G. A., Meijer C., Molema G. and Mulder N. H. (2001) Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis. 4: 91-102
23. Klagsbrun M. and Folkman J. (1990) Angiogenesis. In: Handbook of experimental Pharmacology, pp. 549-586, Sporn M. B. and Roberts A. B. (ed.), Springer, Berlin
24. Ormerod M. G, Collins M. K. L, Rodriguez-Tarduchy G. and Robertson D. (1992) Apoptosis in interleukin-3-dependent haemopoietic cells: quantification by two flow cytometric methods. J. Immunol. Methods. 153: 57-65
25. Vindelov L. L. and Christensen I. J. (1990) A review of techniques and results obtained in onelaboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. Cytometry. 11: 753-770
26. Nehls V. and Drenckhahn D. (1995) A microcarrier-based cocultivation system for the investigation of factors and cells involved in angiogenesis in three-dimensional fibrin matrices in vitro. Histochem. Cell. Biol. 104: 459-466
27. Menager C., Vassy J., Doliger C., Legrand Y. and Karniguian A. (1999) Subcellular localization of RhoA and ezrin at membrane ruffles of human endothelial cells: differential role of collagen and fibronectin. Exp. Cell Res. 249: 221-230
28. Pourtau J., Mirshahi F., Li H., Muraine M., Vincent L., Tedgui A. et al. (1999) Cyclooxygenase-2 activity is necessary for the angiogenic properties of oncostatin M. FEBS Lett. 459: 453-457
29. Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254
30. Passaniti A., Taylor R. M., Pili R., Guo Y., Long P. V., Haney J. A. et al. (1992) A simple quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67: 519-528
31. Dellian M., Witwer B. P., Salehi H. A., Yuan F. and Jain R. K. (1996) Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am. J. Pathol. 149: 59-71
32. Weidner N., Semple J. P., Welch W. R. and Folkman J. (1991) Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 324: 1-8
33. Guay D. P. (2002) Update on fenofibrate. Cardiovasc. Drug Rev. 20: 281-302
34. Harvengt C. and Desager J. P. (1980) Lack of pharmacokinetic interaction of colestipol and fenofibrate in volunteers. Eur. J. Clin. Pharmacol. 17: 459-463
35. V. Clavey C., Copin M. C., Mariotte E., Baugé G., Chinetti J., Fruchart J. C. et al. (1999) Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell Physiol. Biochem 9: 139-149
36. Pasceri V., Cheng J. S., Willerson J. T., Yeh E. T. and Chang J. (2001) Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103: 2531-2534
37. Modur V., Feldhaus M. J., Weyrich A. S., Jicha D. L., Prescott S. M., Zimmerman G. A. et al. (1997) Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J. Clin. Invest. 100: 158-168
38. Goetze S., Eilers F., Bungenstock A., Kintscher U., Stawowy P., Blaschke F. et al. (2002) PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem. Biophys. Res. Commun. 293: 1431-1437
39. Kahn J., Mehraban F., Ingle G., Xin X., Bryant J. E., Vehar G. et al. (2000) Gene expression profiling in an in vitro model of angiogenesis. Am. J. Pathol. 156: 1887-1900
40. Gately S. (2000) The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis. Rev. 19: 19-27
41. Khwaja A., Rodriguez-Viciana P., Wennstrom S., Warne P. H. and Downward J. (1997) Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 15: 16: 2783-2793
42. Fujio Y. and Walsh K. (1999) Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem. 274: 16349-16354
43. Zubilewicz A., Hecquet C., Jeanny J. C., Soubrane G., Courtois Y. and Mascarelli F. (2001) Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a comparative study with VEGF. Oncogene 20: 1403-1413
44. Shiojima I. and Walsh K. (2002) Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 90: 1243-1250
45. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I. P. et al. (1998) Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393: 790-793
46. Combs C. K., Bates P., Karlo J. C. and Landreth G. E. (2001) Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem. Int. 39: 449-457
47. Rossig L., Jadidi A. S., Urbich C., Badorff C., Zeiher A. M. and Dimmeler S. (2001) Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol. Cell. Biol. 21: 5644-5657
48. Flusberg D. A., Numaguchi Y. and Ingber D. E. (2001) Cooperative control of Akt phosphorylation, bcl-2 expression, and apoptosis by cytoskeletal microfilaments and microtubules in capillary endothelial cells. Mol. Biol. Cell 12: 3087-3094
49. Vivanco I. and Sawyers C. L. (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2: 489-501
50. Morales-Ruiz M., Fulton D., Sowa G., Languino L. R., Fujio Y. and Walsh K. et al. (2000) Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ. Res. 86: 892-896